Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation

Blood

Volumn 121, Issue 2, 2013, Pages 360-368

  Rosti, Vittorio ^a   Villani, Laura ^a   Riboni, Roberta ^b   Poletto, Valentina ^a   Bonetti, Elisa ^a   Tozzi, Lorenzo ^c   Bergamaschi, Gaetano ^a   Catarsi, Paolo ^a   Dallera, Elena ^b   Novara, Francesca ^b   Massa, Margherita ^d,e   Campanelli, Rita ^a   Fois, Gabriela ^a   Peruzzi, Benedetta ^d,e   Lucioni, Marco ^b   Guglielmelli, Paola ^c   Pancrazzi, Alessandro ^c   Fiandrino, Giacomo ^b   Zuffardi, Orsetta ^b   Magrini, Umberto ^a   Paulli, Marco ^b   Vannucchi, Alessandro M ^c   Barosi, Giovanni ^a   more..

^a San Matteo Medical Center   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^e Universitaria Meyer   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; PHENYLALANINE; VALINE;

AMINO ACID SUBSTITUTION; ARTICLE; CAPILLARY; CELL CULTURE; CELL SELECTION; CLINICAL ARTICLE; ENDOTHELIUM CELL; FLUORESCENCE ACTIVATED CELL SORTING; GENE MUTATION; GRANULOCYTE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LASER MICRODISSECTION; MYELOFIBROSIS; PRIORITY JOURNAL; SPLEEN; SPLENECTOMY; SPLENIC VEIN; TISSUE SECTION;

EID: 84872353179     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-01-404889     Document Type: Article

References (39)

1. Barosi G, Hoffman R. Idiopathic myelofibrosis. Semin Hematol. 2005;42(4):248-258. (Pubitemid 41400666)
2. Hoffman R, Baker KR, Prchal JT. The polycythemias. In: Hoffman ER, Benz E Jr, Shattil S, et al, eds. Hematology: Basic Principles and Practice. 4th Ed. New York, NY: Churchill Livingstone; 2004:1209-1245.
3. Vainchenker W, Delhommeau F, Costantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118(7):1723-1735.
4. Mesa RHanson CA, Rajkimar SV, Schroeder G, Tefferi A. Evaluation and clinical correlation of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood. 2000;96(10):3374-3380.
5. Barosi G, Rosti V, Massa M, et al. Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia. Br J Haematol. 2004;124(5):618-625. (Pubitemid 38297094)
6. Medinger M, Skoda R, Gratwohl A, et al. Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloprioliferative neoplasms: correlation with clinical parameters and JAK2V617F mutational status. Br J Haematol. 2009;146(2):150-157.
7. Hanahan D, Folkman J. Pattern and emerging mechanism of the angiogenic switch during tumourigenesis. Cell. 1996;86(3):353-364. (Pubitemid 26272076)
8. Gunsilius E, Duba HC, Petzer AL, et al. Evidence from a leukemia model for maintenance of vascular endothelium by bone marrow-derived endothelial cells. Lancet. 2000;355(9216):1688-1691. (Pubitemid 30248482)
9. Fang B, Zheng C, Liao L, et al. Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics. Blood. 2005;105(7):2733-2740. (Pubitemid 40446263)
10. Streubel B, Chott A, Huber D, et al. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med. 2004;351(13):250-259. (Pubitemid 38916042)
11. Rigolin GM, Maffei R, Rizzotto L, et al. Circulating endothelial cells in patients with chronic lympochocytic leukemia. Cancer. 2010;116(8):1926-1937.
12. Della Porta MG, Malcovati L, Rigolin GM, et al. Immunophenotypic, cytogenetic and functional characterization of circulating endothelial cells in myelodisplastic syndromes. Leukemia. 2008;22(3):530-537. (Pubitemid 351386722)
13. Zhang H, Vakil V, Braunstein M, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood. 2005;105(8):3286-3294.
14. Rigolin GM, Fraulini C, Ciccone M, et al. Neoplastic circulating endothelial cells in multiple myeloma. Blood. 2006;107(6):2531-2535. (Pubitemid 43345578)
15. Pezzolo A, Parodi F, Corrias MV, Cinti R, Gambini C, Pistoia V. Tumor origin of endothelial cells in human neuroblastoma. J Clin Oncol. 2007;25(4):376-383. (Pubitemid 350002985)
16. El Hallani S, Boisselier B, Peglion F, et al. A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain. 2010;133(Pt 4):973-982.
17. Soda Y, Marumoto T, Friedmann-Morvinski D, et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U S A. 2011;108(11):4274-4280.
18. Ricci-Vitiani L, Pallini R, Biffoni M, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature. 2010;468(7325):824-828. [Errata in: Nature. 2011;477(7363):238 and Nature. 2011;469(7330):432.]
19. Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature. 2010;468(7325):829-833.
20. Maniotis AJ, Folberg R, Hess A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999;155(3):739-752. (Pubitemid 29426820)
21. Sozer S, Fiel MI, Schiano T, Xu M, Mascarenhas J, Hoffman R. The presence of the JAK2V617F mutation in he liver endothelial cells of patients with Budd-Chiari syndrome. Blood. 2009;113(21):5246-5249.
22. Prindull GA, Fibach E. Are postnatal hemangioblasts generated by dedifferentiation from committed hematopoietic stem cells? Exp Hematol. 2007;35(5):691-701. (Pubitemid 46601745)
23. Ingram DA, Mead LE, Tanaka H, et al. Identification of a novel hierarchy of endothelial progenitor cells using human peripheral and cord blood. Blood. 2004;104(9):2752-2760. (Pubitemid 39434958)
24. Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi CT. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood. 2004;104(7):2073-2080. (Pubitemid 39297859)
25. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1056. [Erratum: Lancet. 2005;366(9480):122.]
26. Lippert E, Boissinot M, Kralovics R, et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. Blood. 2006;108(6):1865-1867. (Pubitemid 44394995)
27. Lucioni M, Novara F, Fiandrino G, et al. Tewnty-one cases of blastic plasmocitoid dendritic cell neoplasm: focus on biallelic locus p21.3 deletion. Blood. 2011;118(17):4591-4594.
28. +) cells in myelofibrosis with myeloid metaplasia. Blood. 2001;98(12):3249-3255.
29. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8(8):618-631.
30. Dudley AC, Udagawa T, Melero-Martin JM et al. Bone marrow is a reservoir for proangiogenic myelomonocytic cells but not endothelial cells in spontaneous tumors. Blood. 2010;116(17):3367-3371.
31. Rosti V, Bonetti E, Bergamaschi G, et al. High frequency of endothelial colony forming cells marks a non-active myeloproliferative neoplasm with high risk of splanchnic vein thrombosis. PLoS One. 2010;5(12):e15277.
32. Piaggio G, Rosti V, Corselli M et al. Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker. Blood. 2009;114(14):3127-3130.
33. Teofili L, Martini M, Iachininoto MG, et al. Endothelial progenitor cells are clonal and exhibit JAK2V617F mutation in a subset of thrombotic patients with Ph-negative myeloproliferative neoplasms. Blood. 2011;117(9):2700-2707.
34. Kohler C, Barekati Z, Radpour R, Zhong XY. Cell-free DNA in the circulation as potential cancer biomarker. Anticancer Res. 2011;31(8):2623-2628.
35. Bautch VL. Tumor stem cells switch sides. Nature. 2010;468(7325):770-771.
36. + haematopoietic progenitor cells in primary myelofibrosis. Br J Haematol. 2011;152(5):665-667.
37. + cells from patients with rpimary myelofibrosis [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):1211-1212.
38. Jelkmann W, Elliott S. Erythropoietin and the vascular wall: the controversy continues [published online ahead of print June 6, 2012]. Nutr Metab Cardiovasc Dis. doi:10.1016/j.numecd.2012.04.002.
39. Kiladjian JJ, Cervantes F, Leebeek FWG, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood. 2008;111(10):4922-4929.